Immuron Limited (IMRN)
Market Cap | 13.15M |
Revenue (ttm) | 1.24M |
Net Income (ttm) | -2.61M |
Shares Out | 5.69M |
EPS (ttm) | -0.44 |
PE Ratio | n/a |
Forward PE | n/a |
Dividend | n/a |
Ex-Dividend Date | n/a |
Volume | 1,476 |
Open | 2.06 |
Previous Close | 2.10 |
Day's Range | 2.05 - 2.08 |
52-Week Range | 1.39 - 3.21 |
Beta | 1.24 |
Analysts | n/a |
Price Target | n/a |
Earnings Date | Dec 19, 2023 |
About IMRN
Immuron Limited, a biopharmaceutical company, engages in the research, development, and commercialization of polyclonal antibodies in Australia, Israel, Canada, the United States, and internationally. The company operates through two segments, Research and Development, and Hyperimmune Products. It offers Travelan, an over-the-counter medicine to reduce the risk of travelers' diarrhea and risk of minor gastrointestinal disorders, as well as a dietary supplement for support digestive health and gastrointestinal tract protection; and Protectyn, an... [Read more]
Financial Performance
In 2023, Immuron's revenue was 1.80 million, an increase of 135.85% compared to the previous year's 765,193. Losses were -3.79 million, 32.7% more than in 2022.
Financial numbers in AUD Financial StatementsNews

Immuron Announces First Patients Enrolled in Campylobacter Challenge Clinical Study
Highlights: First participants enrolled in the US Naval Medical Research Command Clinical Trial Clinical Study initiated to evaluate the efficacy of a new Immuron clinical product to protecting volunt...

Immuron CEO, Steven Lydeamore Investor Webinar Presentation
MELBOURNE, Australia, Nov. 28, 2023 (GLOBE NEWSWIRE) -- Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian based and globally integrated biopharmaceutical company is pleased to invite shareholder...

Immuron CEO Steven Lydeamore Investor Webinar Presentation
MELBOURNE, Australia, Nov. 13, 2023 (GLOBE NEWSWIRE) -- Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian based and globally integrated biopharmaceutical company is pleased to invite shareholder...

Immuron CEO Steven Lydeamore presented at AusBioInvest
MELBOURNE, Australia, Oct. 30, 2023 (GLOBE NEWSWIRE) -- Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian based and globally integrated biopharmaceutical company, is pleased to advise our Chief ...

Immuron Announces Travelan® Clinical Study Cohort 2 commences
Highlights: Second cohort of 34 healthy volunteers enrolled in the Travelan® Clinical Trial Clinical Trial to examine a dosing regimen for Travelan® more suited to the US military has commenced the se...

Immuron achieves record quarterly Travelan® sales
Highlights: Record quarterly Travelan® sales of $1,550,240 Total sales of A$1,565,767 in Q1, FY24 $1,508,933 increase on Q1, FY23 sales 130% higher than pre-pandemic period Q1, FY20 sales MELBOURNE, A...

Immuron Limited Announces Participation in the LD Micro Main Event XVI
Presentation on Wednesday, October 4th at 11:00 PT Melbourne, Australia--(Newsfile Corp. - September 18, 2023) - Immuron Limited (NASDAQ: IMRN), an Australian based and globally integrated biopharmace...

Immuron achieves record monthly Travelan® sales
Highlights: Record monthly Travelan® sales Australian sales of A$1.18 M in August 2023 (7984% increase on August 2022 sales) MELBOURNE, Australia, Sept. 13, 2023 (GLOBE NEWSWIRE) -- Immuron Limited (A...

Immuron CEO, Steven Lydeamore to present at H.C. Wainwright
MELBOURNE, Australia, Sept. 11, 2023 (GLOBE NEWSWIRE) -- Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian based and globally integrated biopharmaceutical company is pleased to advise our Chief ...

Immuron to present at the Military Health System Research Symposium
MELBOURNE, Australia, Aug. 14, 2023 (GLOBE NEWSWIRE) -- Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian based and globally integrated biopharmaceutical company is pleased to announce that it w...

Immuron Announces First Patients Enrolled in Travelan® Clinical Study
Highlights: First cohort of 30 healthy volunteers enrolled in the Travelan® Clinical Trial Clinical Trial to examine a dosing regimen for Travelan® more suited to the US military has commenced Final 3...

Immuron CEO, Steven Lydeamore to present at Bioshares
MELBOURNE, Australia, July 24, 2023 (GLOBE NEWSWIRE) -- Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian based and globally integrated biopharmaceutical company is pleased to advise our Chief E...

Immuron Business Update - Ateria Health launches Juvia™ in Australia
Highlights: Ateria has launched Juvia™ containing breakthrough natural ingredient ERME™ in Australia New clinical study is underway with the NHS in Swansea, Wales in people diagnosed with IBS due to m...

Immuron FY23 Sales increase 136% on FY22 Sales
Highlights: Australian FY23 sales of A$1.16 M (478% increase on FY22 sales) USA FY23 Travelan® sales of A$643 k (28% increase on FY22 sales) Global FY23 sales of A$1.80 M (136% increase on FY22 sales)...

Immuron Chairman Transition
MELBOURNE, Australia, June 30, 2023 (GLOBE NEWSWIRE) -- Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian based and globally integrated biopharmaceutical company, is pleased to announce the tran...

Immuron Business Update: Letter to Shareholders
Highlights: Immuron Board approves IMM-529 cGMP manufacturing and to proceed with FDA pre-IND submission Recruitment and screening update for Travelan® Controlled Human Infection Model (CHIM) Clinical...

Immuron Initiates Recruitment of Travelan® Clinical Study
Highlights: Immuron receives approval from U.S. Army Medical Research and Development Command Recruitment and screening of healthy volunteers for Travelan® Controlled Human Infection Model (CHIM) Clin...

Immuron Limited Announces Participation in the LD Micro Invitational XIII
Melbourne, Australia--(Newsfile Corp. - May 16, 2023) - Immuron Limited (ASX: IMC) (NASDAQ: IMRN) announced today that it will be presenting at the 13th Annual LD Micro Invitational at the Luxe Sunset...

Immuron stock rockets after FDA removes hold on IND of infectious diarrhea treatment
The U.S.-listed shares of Immuron Ltd. IMRN powered up 66.3% toward a one-year high in premarket trading Monday, after the Australia-based biopharmaceutical company said the U.S. Food and Administrati...

Immuron Announces FDA Removed Clinical Hold on New Campylobacter ETEC Therapeutic Paves way for Clinical Trial Initiation
Highlights: U.S. Food and Drug administration (FDA) remove clinical hold on New Campylobacter ETEC Therapeutic IND application US Naval Medical Research Centre (NMRC) satisfactorily addressed all clin...

Immuron CEO, Steven Lydeamore to present at Coffee Microcaps
MELBOURNE, Australia, May 02, 2023 (GLOBE NEWSWIRE) -- Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian based and globally integrated biopharmaceutical company that has developed two commercial...

Immuron Q3 FY23 Business Update Presentation
MELBOURNE, Australia, April 19, 2023 (GLOBE NEWSWIRE) -- Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian based and globally integrated biopharmaceutical company that has developed two commerci...

Q3 FY23 Business Update Webinar Notification
MELBOURNE, Australia, April 11, 2023 (GLOBE NEWSWIRE) -- Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian based and globally integrated biopharmaceutical company that has developed two commerci...

Immuron CEO, Steven Lydeamore to host an investor webinar
MELBOURNE, Australia, Feb. 15, 2023 (GLOBE NEWSWIRE) -- Immuron Limited (ASX: IMC; NASDQ: IMRN), an Australian based and globally integrated biopharmaceutical company that has developed two commercial...